Pulmonary Hypertension as a Predictor of Early Outcomes of Mitral Valve Replacement: A Study in Rheumatic Heart Disease Patients

Platelet survival time (SURV) has correlated with a history of thromboembolism (TE) in patients with rheumatic heart disease (RHD). A controlled trial of sulfinpyrazone (SFP) in RHD is in progress and 138 patients have been entered. SURV (51Chromium labelling) was shortened (2.3 ± 0.08 days; AVE t 1/2 ± SEM; normal 3.7 ± 0.04 days) in 40 of 41 (98%) with a history of TE and in 76 of 97 (78%) (2.9 ± 0.07 days; P<0.001) of those without a history of TE. One hundred sixteen with shortened SURV have been randomized to SFP or placebo and 67 have either completed four years (N=37), undergone mitral valve replacement (N=18) (ave 19 months; range 6-32 months), had definite TE (N=8) (average 14 months; range 8-23 months) or died (N=4) (average 15 months; range 5-22 months). Definite TE (prolonged neurologic deficit) occurred in one on SFP and in seven on placebo (all with shortened SURV) (X2 = 4.31; NS). SFP increased SURV (2.4 ± 0.12 to 2.7 ± 0.13 days; N=23; P<0.001) and 12 (52%) had an increase in SURV of >0.02 days. The patient on SFP with new TE had no change in SURV (2.3 to 2.3 days). Placebo did not alter SURV (2.4 ± 0.15 to 2.5 ± 0.08 days; N=26; NS) and two (8%) had an alteration of SURV by > 0.02 days. SURV was not altered in patients with normal SURV (3.7 ± 0.08 to 3.6 ± 0.08 days; N=12; NS) and no patient with normal SURV has had shortened SURV on subsequent yearly measurement. Patients with normal SURV were not randomized. Results suggest that SURV is shortened in patients with RHD who have had or will have TE, that SFP increases SURV and may prevent TE in these patients.

Download Full-text

Clinical study of appropriate length artificial chordae tendineae implantation in Mitral Valve Replacement for rheumatic heart disease

10.22541/au.160067357.76919539 ◽

2020 ◽

Author(s):

Zulei Zhang ◽

Fajia Hu ◽

Wei Yang ◽

Yi Gong ◽

Chao Lu ◽

...

Keyword(s):

Heart Disease ◽

Clinical Study ◽

Mitral Valve ◽

Rheumatic Heart Disease ◽

Valve Replacement ◽

Mitral Valve Replacement ◽

Chordae Tendineae ◽

Artificial Chordae ◽

Rheumatic Heart

Download Full-text

Mitral valve replacement for rheumatic heart disease in Southern Africa

Journal of Cardiothoracic Surgery ◽

10.1186/1749-8090-8-s1-o294 ◽

2013 ◽

Vol 8 (S1) ◽

Author(s):

P Zilla ◽

J Koshy ◽

J Brink ◽

P Human

Keyword(s):

Heart Disease ◽

Mitral Valve ◽

Rheumatic Heart Disease ◽

Valve Replacement ◽

Mitral Valve Replacement ◽

Southern Africa ◽

Rheumatic Heart

Download Full-text

Positive Outcomes of Goal Directed Cardiac Rehabilitation for a Patient Undergone Rheumatic Heart Disease Undergone Mitral Valve Replacement: A Case Study

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2021/v33i59a34331 ◽

2021 ◽

pp. 798-802

Author(s):

Grisha Ratnani ◽

Rashmi Walke ◽

Moli Jai Jain ◽

Vishnu Vardhan ◽

Vaishnavi Yadav ◽

...

Keyword(s):

Quality Of Life ◽

Heart Disease ◽

Mitral Valve ◽

Cardiac Rehabilitation ◽

Rheumatic Heart Disease ◽

Valve Replacement ◽

Mitral Valve Replacement ◽

Rheumatic Heart

Rheumatic heart disease is one of the principal contributors that has a negative influence on a patient's quality of life and makes it challenging for them to perform their daily activities. The disorder predominantly impairs the function of heart valves, specifically the mitral valve, resulting in stenosis that can be managed by repair or replacement of the valve. The purpose of treatment is to improve the patient's quality of life. As an adjunct to that, cardiac rehabilitation and exercise therapy are used. This case study discusses a patient with mitral stenosis and mitral regurgitation, who underwent mitral valve replacement. She was given with physiotherapy for a week of phase I cardiac rehabilitation and was prescribed home exercise.

Download Full-text